Integra LifeSciences Holdings Corporation
IART
$15.10
-$0.02-0.13%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.42% | -1.74% | 5.57% | -0.61% | 3.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.42% | -1.74% | 5.57% | -0.61% | 3.74% |
| Cost of Revenue | -2.39% | 10.21% | 5.79% | 11.36% | 12.41% |
| Gross Profit | 6.17% | -9.36% | 5.41% | -8.61% | -2.14% |
| SG&A Expenses | 3.51% | -2.89% | 1.21% | -2.65% | 2.81% |
| Depreciation & Amortization | 1.94% | 1.43% | -0.85% | 1.27% | 21.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.01% | 1.90% | 1.82% | 3.22% | 6.94% |
| Operating Income | 29.57% | -21.50% | 58.76% | -30.74% | -22.28% |
| Income Before Tax | 91.98% | -80.88% | 66.49% | -3,396.56% | -474.30% |
| Income Tax Expenses | 146.55% | 93.63% | 85.31% | -1,584.48% | -143.36% |
| Earnings from Continuing Operations | 81.75% | -108.77% | 49.47% | -3,803.18% | -670.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.75% | -108.77% | 49.47% | -3,803.18% | -670.89% |
| EBIT | 29.57% | -21.50% | 58.76% | -30.74% | -22.28% |
| EBITDA | 15.36% | -18.55% | 28.36% | -8.44% | -3.38% |
| EPS Basic | 81.86% | -108.73% | 49.68% | -3,839.89% | -683.89% |
| Normalized Basic EPS | 53.63% | -37.13% | 61.07% | -55.90% | -42.28% |
| EPS Diluted | 81.86% | -109.10% | 49.71% | -3,839.89% | -683.89% |
| Normalized Diluted EPS | 53.63% | -37.13% | 61.07% | -55.90% | -42.28% |
| Average Basic Shares Outstanding | 0.64% | 0.47% | 0.40% | -0.92% | -1.64% |
| Average Diluted Shares Outstanding | 0.64% | 0.47% | 0.40% | -0.92% | -1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |